Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EPS (Basic) : €0.01 (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co EPS (Basic)?

Biocytogen Pharmaceuticals (Beijing) Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was €0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.01.

Biocytogen Pharmaceuticals (Beijing) Co's EPS (Diluted) for the six months ended in Dec. 2024 was €0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.01.

Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the six months ended in Dec. 2024 was €0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was 0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Biocytogen Pharmaceuticals (Beijing) Co's highest 3-Year average EPS without NRI Growth Rate was -0.10% per year. The lowest was -0.10% per year. And the median was -0.10% per year.

Biocytogen Pharmaceuticals (Beijing) Co EPS (Basic) Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co EPS (Basic) Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-0.14

-0.19

-0.21

-0.12

0.01

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial				-0.11	-0.06	-0.06	-0.02	0.03

Biocytogen Pharmaceuticals (Beijing) Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Biocytogen Pharmaceuticals (Beijing) Co's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(4.4	-	0)	/	398.011
	=	0.01

Biocytogen Pharmaceuticals (Beijing) Co's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(11.046	-	0)	/	397.755
	=	0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.01

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Biocytogen Pharmaceuticals (Beijing) Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines